Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Biosimilar Education Needed To Eliminate 'Nocebo' Effect, Pfizer Says

Executive Summary

Material to help providers and patients understand scientific issues can inspire more confidence in the products, exec says.

You may also be interested in...



Enthusiasm For US Biosimilars Wanes For Some, But Not Others

Three years after the first biosimilar launched in the US, the market has failed to deliver notable return on investments. Some players like Mylan are going public with frustrations over market barriers, while others, like Amgen, say they are encouraged by steady progress. Teva, however, is limiting its investment in biosimilars.

Biosimilar Hearing Will Consider Whether 'Umbrella' Exclusivity Policy Warranted

US FDA asks for comments on whether the policy employed for small molecule generics also should apply to biosimilars.

Biosimilars: US FDA Education Campaign Is Non-Committal On Non-Medical Switching

Substituting a biosimilar for a reference product is a state issue and outside agency's purview, FDA says.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB002499

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel